AMAG: FDA Delays Feraheme Decision
AMAG Pharmaceuticals (AMAG) expects the U.S. Food and Drug Administration to make its approval decision on the company's iron replacement therapy Feraheme within the next few days, the company said Monday night.
The FDA's decision was supposed to come Monday but has been delayed for administrative reasons, said AMAG, based on the company's contact with the agency in recent days.
The FDA has not requested any additional information from AMAG and no outstanding issues remain regarding Feraheme, according to the company.
AMAG CEO Brian Pereira, on a Tuesday morning conference call, said the company was disappointed in the delay but that the company will be ready to launch Feraheme commercially within weeks of FDA approval.Feraheme is an injectable iron replacement therapy that will be used to correct anemia in patients with chronic kidney disease. But the FDA must approve Feraheme before it can be sold, so what does this latest delay mean for AMAG? Two possible scenarios: First, this latest delay is simply an administrative backlog at the FDA, per AMAG's assertion. It is taking longer than expected to get all the signatures and sign-offs necessary for Feraheme's full approval, so this latest, short delay is no big deal. Second, the FDA does have a significant (and un-identified) problem with Feraheme's approval so the drug is now in regulatory limbo. A delay could stretch on for months, as has happened with Cardiome's (CRME) drug for atrial fibrillation. The second scenario cannot be completely discounted, but it seems unlikely at this point, especially since AMAG resolved in April all the Feraheme manufacturing issues that had previously delayed the product's approval.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV